Copyright
©The Author(s) 2017.
World J Clin Oncol. Aug 10, 2017; 8(4): 343-350
Published online Aug 10, 2017. doi: 10.5306/wjco.v8.i4.343
Published online Aug 10, 2017. doi: 10.5306/wjco.v8.i4.343
Indications |
Unresectable liver metastases |
Liver-dominant metastatic disease |
Minimum of three different chemotherapies before |
No systemic chemotherapy available |
Symptomatic liver metastases |
Contraindications |
ECOG >1 |
Tumour burden of the liver > 75% |
Poor liver function (quick < 40%, PTT < 45 s, albumin < 2 g/dL) |
Extensive amounts of ascites |
Obstructive icterus (bilirubin > 3 mg/dL) |
Acute infection |
Myelodepression (leucocytes < 2000/mL, platelets < 100000/μL) |
Limited kidney function (creatinine > 2 mg/dL) |
Extensive heart insufficiency ( > NYHA II) |
- Citation: Gruber-Rouh T, Langenbach M, Naguib NNN, Nour-Eldin NEM, Vogl TJ, Zangos S, Beeres M. Trans-arterial chemoperfusion for the treatment of liver metastases of breast cancer and colorectal cancer: Clinical results in palliative care patients. World J Clin Oncol 2017; 8(4): 343-350
- URL: https://www.wjgnet.com/2218-4333/full/v8/i4/343.htm
- DOI: https://dx.doi.org/10.5306/wjco.v8.i4.343